Whitepaper

Navigating the Landscape of Clinical Trial Applications under the EU Clinical Trials Regulation: Insights and Challenges

Published 15th April 2024

Whitepaper - Navigating the Landscape of Clinical Trial Applications under the EU Clinical Trials Regulation Insights and Challenges

Ahead of the 31st of January 2024 marking a year until all EU clinical trials need to be compliant with the EU Clinical Trials Regulation (CTR), this whitepaper delves into different aspects we have observed that can become ‘sticking points’ for Sponsors wanting to conduct clinical trials under the CTR. Our analysis has highlighted six key topics, encompassing our experience of the overall clinical trial application (CTA) assessment process, data transparency and publication, transitioning from the Clinical Trial Directive (CTD) to the CTR, the EU CTR Systems Environment, EU Legal Representative requirements, and Article 32 paediatric requirements.

 

Complete the form to download our free whitepaper

    Please check this box to submit the form and agree to communications from DLRC and the storage and handling of your data, in accordance with our Privacy Policy.

    Submit

    Thank you for your interest in our whitepaper

    Need personalised assistance to prepare for the new regulation? Contact our experts at hello@dlrcgroup.com

    Download now

    Meet Our Experts

    James Biddlecombe Business Transformation and CTR Lead DLRC Ltd, DLRC Group
    James Biddlecombe

    Business Transformation and CTR Lead, DLRC Ltd, DLRC Group

    James’s journey with the EU CTR started in 2017, working at the EMA in the CTIS business team. Over the last six years, he supported the development of the regulation and guidance, the development of CTIS, and has supported clients with CTR readiness and CTA submissions. He has supported numerous clients in getting them ready for the CTR Go-Live through training, redesign of operating models, and updates to processes and procedures. More recently, he supports clients with strategic direction for trials submitted under the CTR and helps to navigate EU CTR guidelines and ensure CTA document compliance with the regulation.

    Contact James
    Wafa Bouaziz, Managing Director & Head of Regulatory Affairs, Orphix Consulting GmbH, DLRC Group
    Wafa Bouaziz

    Managing Director & Head of Regulatory Affairs, Orphix Consulting GmbH, DLRC Group

    Wafa is a global regulatory professional with a broad experience across various therapeutic areas including rheumatology, anti-infective, dermatology and oncology. With her strong scientific, regulatory, and managerial expertise she successfully led both early development projects (CTA and IND submissions) and full development programs (MAA and NDA/BLA). She has supported clients with several investigational products through their European regulatory journey, advising on CTA requirements from a strategic perspective. She also acts as the EU legal representative under CTR and helps companies ensuring compliance with the new regulation.

    Contact Wafa

    Stay Informed

    Sign up to our bimonthly newsletter for the latest news and industry insights

      Please check this box to submit the form and agree to communications from DLRC and the storage and handling of your data, in accordance with our Privacy Policy.

      Thank you for your submission.

      Latest news

      View all